Doc Logic,
"All that really needs to be compared between cancer types is the activation/maturation characteristics of the end product DCs which are known to produce treatment effect. The necessary activation/maturation characteristics of the DCs is the same for all solid tumor cancer types. When this becomes better known do you really think regulators and insurance coverage will be able to stand in the way? Safety is NOT an issue to prevent rapid extensions of labels which is unlike checkpoint inhibitors and CAR-T and evidence points to immediately available increased benefit for those being given Poly ICLC."
I think there are still some major considerations such as whether primary or secondary treatment is originally sought or both, whether SOC + DCVax adjuvant treatment is sought initially, and, whether new combo treatments per cancer will be clinically tested rapidly. However your comments are powerful and certainly shows all that the doors can potentially be wide open to rapid adoption of DCVax as part of any solid tumor therapy. Thx, this helps us to think bigger because it is the key to the door.
GLTA
Market Data 
Markets 
AI
